Evidence map›Paper›PMID 39026877›Full record

ArticlebioRxiv : the preprint server for biology2024

Design, infectability, and transcriptomic analysis of transregionally differentiated and scalable lung organoids derived from adult bronchial cells.

Alicia Reyes Valenzuela, Mark Turner, Nathan Markarian, Christophe Lachance-Brais, John Hanrahan, Hojatollah Vali, Silvia Vidal, Luc Mongeau

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alicia Reyes ValenzuelaBiological and Biomedical Engineering, McGill University, Montreal, Quebec, Canada. H3A 2B4.ORCID 0000-0001-6479-1583
Mark TurnerPharmaceutical Drugs Directorate, Bureau of Gastroenterology, Infection and Viral Diseases, Health Canada, Ottawa, Ontario, Canada, K1A 0K9.
Nathan MarkarianDepartment of Human Genetics, McGill University, Montreal, Canada, H3A 0C7.ORCID 0000-0001-8072-4268
Christophe Lachance-BraisChemistry Department, McGill University, Montreal, Quebec, Canada. H3A 0B8.
John HanrahanDepartment of Physiology, McGill University, Montreal, Canada. H3G 1Y6.
Hojatollah ValiDepartment of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada. H3A 0C7.
Silvia VidalDepartment of Human Genetics, McGill University, Montreal, Canada, H3A 0C7.
Luc MongeauBiological and Biomedical Engineering, McGill University, Montreal, Quebec, Canada. H3A 2B4.

Funding

Bioprintable composite materials and microfluidic tools for vocal fold restoration and repairR01DC018577 · NIDCD · MCGILL UNIVERSITY · PI MONGEAU, LUC · 2021 to 2025
$2.5M
NIDCD NIH HHS R01 DC018577
6 · The paper itself

Abstract

The lung is a primary target for many lethal respiratory viruses, leading to significant global mortality. Current organoid models fail to completely mimic the cellular diversity and intricate tubular and branching structures of the human lung. Lung organoids derived from adult primary cells have so far only included cells from the input cell region, proximal or distal. Existing models are expensive. They often require cells from invasive deep lung tissue biopsies. The present study aimed to address these limitations. The lung organoids obtained using an original protocol exhibited transregional differentiation and were derived from relatively more accessible primary cells from the trachea/bronchi. Immortal bronchial cell lines were also used to simplify organoid fabrication and improve its scalability. The lung organoids are formed starting from bronchial cells with fibroblasts feeder cells in an alginate hydrogel coated with base membrane zone proteins. Characterizations were performed using bulk RNA sequencing and tandem mass tags. The resulting organoids express markers of different lung regions and mimic to some extent the tubular and branching morphology of the lung. The proteomic profile of organoid from primary cells and from cell lines was found to evolve towards that of mature lung tissue. Upregulated genes were mostly related to the respiratory system, tube development, and various aspects of respiratory viral infections. Infection with SARS-CoV-2 and influenza H1N1 was successful and did not require organoid disassembly. The organoids matured within 21 days and did not require complex or expensive culture methods. Transregionally differentiated lung organoid may find applications for the study of emerging or re-emerging viral infections and fostering the development of novel in-vitro therapeutic strategies.

Identifiers

PMID39026877
PMCPMC11257428

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.